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ABSTRACT
Using micro data on virtually all of the drugs and diseases of over 500,000 people enrolled in Puerto
Rico's Medicaid program, we examine the impact of the vintage (original FDA approval year) of
drugs  used  to  treat  a  patient  on  the  patient's  3-year  probability  of  survival,  controlling  for
demographic characteristics (age, sex, and region), utilization of medical services, and the nature and
complexity of illness. We find that people using newer drugs during January-June 2000 were less
likely to die by the end of 2002, conditional on the covariates. The estimated mortality rates are
strictly declining with respect to drug vintage. For pre-1970 drugs, the estimated mortality rate is
4.4%. The mortality rates for 1970s, 1980s, and 1990s drugs are 3.6%, 3.0%, and 2.5%, respectively.
The actual mortality rate is about 16% (3.7% vs. 4.4%) lower than it would have been if all of the
drugs utilized in 2000 had been pre-1970 drugs. Estimates for subgroups of people with specific
diseases display the same general pattern.
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Clinical studies of specific new drugs have shown that these drugs increase 
survival rates.  Here are three examples: 
 
•  Stenestrand et al (2001) studied the impact on survival of statin treatment 
following acute myocardial infarction.  They found that 1-year mortality was 
9.3% in the no-statin group and 4.0% in the statin treatment group. 
•  Grier et al (2003) found that adding two experimental drugs to the standard four-
drug chemotherapy regimen has significantly improved survival in patients with 
non-metastatic Ewing's sarcoma, a highly malignant bone cancer of children and 
young adults.  The overall survival rate increased from 61 percent to 72 percent 
for Ewing's sarcoma patients with localized disease who underwent the 
experimental six-drug chemotherapy. 
•  The journal U.S. Pharmacist (2002) reported that patients suffering from 
advanced metastatic melanoma who were treated with a combination of an 
investigational agent, Ceplene, and interleukin-2 (IL-2) had twice the survival rate 
as patients who were treated with IL-2 only. The patients were enrolled in a three-
year study. The study also showed that the Ceplene/IL-2 combination 
significantly increased survival in a subpopulation group of advanced metastatic 
melanoma patients with liver metastases. The rate of survival in this group was 
six times that of the group given IL-2 only. 
 
Also, I have performed several studies using aggregate data (Lichtenberg (2002-
2004)) that indicated that the introduction of new drugs has increased longevity.  The 
objective of the present study is to examine the impact of the vintage (original FDA 
approval year) of drugs used to treat a patient on the patient’s probability of survival, 
using micro data on virtually all drugs and diseases from Puerto Rico’s Medicaid 
program, which covers about 1.5 million people.
1, 2 
 
I.  Econometric framework 
 
To determine the effect of the vintage distribution of a person’s prescribed 
medicines on probability of death, conditional on demographic characteristics (age, sex, 
and region), utilization of medical services, and the nature and complexity of illness, I 
will estimate the following model: 
                                                 
1 I am grateful to the Puerto Rico Health Insurance Administration (ASES) for providing me access to the 
data.  ASES does not necessarily endorse or accept the conclusions of this study. 
2 I hypothesize that survival also depends on the vintage (year of invention or market introduction) of 
medical products and services other than drugs, such as laboratory tests and radiological and surgical 
procedures.  Unfortunately our ability to measure the vintage of these other products and services is much 
more limited than out ability to measure the vintage of drugs.  I plan to address this issue in future research.     3
 




DIEDi  = 1 if individual i died during the period 2000-2002 
  = 0 otherwise 
POST1970i  = the fraction of individual i’s prescribed medicines whose active 
ingredients were approved by the FDA after 1970 
POST1980i  = the fraction of individual i’s prescribed medicines whose active 
ingredients were approved by the FDA after 1980 
POST1990i  = the fraction of individual i’s prescribed medicines whose active 
ingredients were approved by the FDA after 1990 
Zi  = a vector of covariates  
εi  = a disturbance 
 
Suppose individual A consumed only medicines approved in 1985.  For that individual, 
POST70 = POST80 = 1, and POST90 = 0.  Hence E(DIEDA | ZA) = β1970 + β1980.   
Suppose individual B consumed only medicines approved in 1995.  For that individual, 
POST70 = POST80 = POST90 = 1.  Hence E(DIEDB | ZB) = β1970 + β1980 + β1990, and 
E(DIEDB | ZB) - E(DIEDA | ZA) = β1990.  The parameter β1990 may be interpreted as the 
difference between the death probability of people consuming only post-1990 medicines 
and that of people consuming only pre-1991 medicines.  More generally: 
 







…then E(DIEDi | Zi) =  
1965 k 
1975  k + β1970  
1985  k + β1970 + β1980  
1995  k + β1970 + β1980 + β1990 
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The 
parameter… 
…may be interpreted as this difference:  
β1970  1970s drugs vs. pre-1970 drugs death probability 
β1980  1980s drugs vs. 1970s drugs death probability 
β1990  1990s drugs vs. 1980s drugs death probability 
 
II.  Data and measurement 
 
ASES provided me with all medical and pharmacy claims of ASES beneficiaries 
during the period January 1-June 30, 2000.  There were about 12.2 million claims.   
Demographic information.  The following demographic variables could be 
determined from the claims records: 
•  The person’s sex 
•  The person’s age 
•  The geographic region in which services were provided 
 
Unfortunately, we lack data on other personal attributes, such as education and 
income.    But unobserved heterogeneity with respect to income is limited by the fact that, 
to be eligible for Medicaid in Puerto Rico, annual income of a family of four could not 
exceed $16,440 (in the year 2002).   
 
Person’s utilization of services. 
 
•  The person’s number of medical claims (physician encounters) 
•  The person’s number of hospital admissions 
•  The person’s number of pharmacy claims 
 
Vintage distribution of pharmacy claims.  Each pharmacy claim
3 included the 
National Drug Code (NDC).  I determined the active ingredient(s) contained in each 
NDC from Multum’s Lexicon.  I determined the earliest FDA approval date of each 
active ingredient from standard commercial pharmaceutical databases, i.e. Gold Standard 
Multimedia’s Clinical Pharmacology 2000 and Mosby's Drug Consult.  Using this 
information, I calculated, for each pharmaceutical claim, the values (0 or 1) of POST70, 
POST80, and POST90.  I then calculated, for each individual, the average values of 
                                                 
3 I examined outpatient pharmacy claims (which contain NDC codes), but not hospital and medical claims 
for drugs administered by providers (e.g. chemotherapy), which contain J-codes and other HCPCS codes.  
In future research I plan to account for all drug claims.     5
POST70, POST80, and POST90, i.e. the fraction of the individual’s Rx’s that were for 
drugs approved after 1970, 1980, and 1990. 
Nature of person’s illnesses.  The medical claims include ICD9 (diagnosis) 








1  001-139  infectious and parasitic diseases  
2 140-239  neoplasms   
3  240-279  endocrine, nutritional and metabolic diseases, and immunity 
disorders  
4  280-289  diseases of the blood and blood-forming organs  
5  290-319  mental disorders  
6  320-389  diseases of the nervous system and sense organs  
7  390-459  diseases of the circulatory system  
8  460-519  diseases of the respiratory system  
9  520-579  diseases of the digestive system  
10  580-629  diseases of the genitourinary system  
11  680-709  diseases of the skin and subcutaneous tissue  
12  710-739  diseases of the musculoskeletal system and connective tissue 
13  740-759  congenital anomalies  
14  760-779  certain conditions originating in the perinatal period  
15  780-799  symptoms, signs, and ill-defined conditions  
 
I then calculated DISEASE_SHAREij (j = 1, 2,…, 15): the fraction of person i’s 
diagnoses that were in each disease category.  For example, if all of person i’s diagnoses 
were diabetes, then DISEASE_SHAREij = 1 if j = 3 and DISEASE_SHAREij = 0 if j ≠ 3.  
If person i had 3 circulatory diagnoses and one digestive diagnosis, then 
DISEASE_SHAREij = 0.75 if j = 7, DISEASE_SHAREij = .25 if j = 9, and 
DISEASE_SHAREij = 0 for all other j.   
In addition to measuring the shares of diagnoses in each disease category, I 
calculated the person’s “effective number” of diseases.  Rather than simply counting the 
number of disease categories in which a person’s diagnoses fell, I computed the 
following index: 
 
N_DISEASEi = 1 / Σj DISEASE_SHAREij
2
 
                                                 
4 I excluded women with diagnoses of complications of pregnancy, childbirth, and the puerperium (ICD9 
codes 630-677) from the sample.   6
 
If all of a person’s diagnoses fell in one disease category, then N_DISEASEi = 1.  If half 
of a person’s diagnoses fell in one disease category, and half fell in a second category, 
then N_DISEASEi = 2.  If 90% of a person’s diagnoses fell in one disease category, and 
10% fell in a second category, then N_DISEASEi = 1 / (.9
2 + .1
2) = 1.22. 
Mortality.  The Department of Health provided me with a list of (encrypted) 
social security numbers of all Puerto Rican residents who died during the period 2000-
2002.  I merged this list with the January 1-June 30, 2000 ASES claims data; this allowed 
me to determine whether or not an ASES beneficiary who had utilized services during 
January 1-June 30, 2000 had died by the end of 2002: 
 
DIEDi = 1 if person i died by the end of 2002 
 
           = 0 otherwise 
 
Descriptive statistics.  Sample means of the variables are shown in the following table.
5 
 







Number of medical claims  4.2 
Number of pharmacy claims  4.6 
Number of hospital claims  0.24 
N_DISEASE 1.76 
infectious and parasitic diseases  4.3% 
neoplasms  1.1% 
endocrine, nutritional and metabolic diseases, and 
immunity disorders  6.9% 
diseases of the blood and blood-forming organs  1.0% 
mental disorders  4.7% 
diseases of the nervous system and sense organs  5.6% 
diseases of the circulatory system  9.0% 
                                                 
5 For all variables except POST70, POST80, and POST90, the sample size is approximately 794,000.  For 
POST70, POST80, and POST90, the sample size is approximately 542,000: about a third of beneficiaries 
had no pharmaceutical claims.   7
diseases of the respiratory system  16.9% 
diseases of the digestive system  4.6% 
diseases of the genitourinary system  6.8% 
diseases of the skin and subcutaneous tissue  2.8% 
diseases of the musculoskeletal system and connective 
tissue 6.8% 
congenital anomalies  0.4% 
certain conditions originating in the perinatal period  0.1% 
symptoms, signs, and ill-defined conditions  7.5% 
 
The three-year mortality rate is 3.1%.  This seems consistent with published mortality 
data for Puerto Rico.  According to the United Nations, the crude (annual) death rate in 
Puerto Rico during 2000-2005 under “medium variant” mortality assumptions is 8.3 per 
1,000 population.
6  This implies a three-year mortality rate of approximately 2.49% (= 3 
* 0.83%).  Mortality of ASES beneficiaries may be somewhat higher than that of other 
residents of Puerto Rico. 
We can compare the vintage distribution of drugs used by ASES beneficiaries to 
the vintage distribution of drugs used by all Americans and by American Medicaid 
beneficiaries using the 2000 Prescribed Medicines file of the Household Component of 
the Medical Expenditure Panel Survey (MEPS), which is conducted by the Agency for 
Healthcare Research and Quality.  This comparison is shown in Figure 1.  The fraction of 
ASES Rx’s that were approved after 1970 (63.2%) is similar to the fraction of U.S. 
Medicaid Rx’s that were approved after 1970 (61.7%).  However, the fractions of ASES 
Rx’s that were approved after 1980 and 1990 (29.7% and 8.2%) are much smaller than 
the fractions of U.S. Medicaid Rx’s
7 that were approved after 1980 and 1990 (48.4% and 
25.5%).  Use of older drugs in Puerto Rico’s Medicaid program may be partly 
attributable to the fact that, in Puerto Rico, the physician bears the costs of the drugs—the 





                                                 
6 Source: Population Division of the Department of Economic and Social Affairs of the United Nations 
Secretariat, World Population Prospects: The 2002 Revision and World Urbanization Prospects: The 2001 
Revision, http://esa.un.org/unpp, 25 May 2003; 12:23:46 PM. 
7 We consider any Rx for which Medicaid paid at least part of the cost to be a Medicaid Rx.   8
III.  Empirical results 
 
OLS estimates of the mortality model based on the entire population of ASES 
beneficiaries with pharmaceutical claims (N = 539,750) are shown in Table 1.
8  The 
dependent variable is DIED: a dummy variable equal to one if the person died during 
2000-2002, otherwise equal to zero.
9  In addition to the three drug-vintage variables 
(POST70, POST80, and POST90), the model includes: three utilization variables 
(number of medical, pharmacy, and hospital claims), 15 diagnosis category variables, the 
index of the number of diseases (N_DISEASE), 9 region dummy variables, and 200 
single-year-of-age-by-sex dummy variables (not shown to conserve space).   
The coefficients of all three drug-vintage variables are negative and highly 
significant (p-value < .0001), which is consistent with the hypothesis that ASES 
beneficiaries using newer drugs during January-June 2000 were less likely to die by the 
end of 2002, conditional on the covariates.  Before considering the implications of the 
drug-vintage coefficients in detail, we will discuss salient features of the coefficients on 
the covariates. 
The coefficients on all three utilization variables are positive and highly 
significant: people who used more medical services during January-June 2000 were more 
likely to die by the end of 2002.  For example, one additional medical claim (physician 
visit) is associated with a .0031 (about 8%) increase in the probability of death.  Although 
utilization of medical services presumably reduces mortality, given initial (pre-treatment) 
health status, people in the worst initial health utilize the most medical services.  
Including the three utilization variables (as well as the diagnosis category and 
demographic variables) is therefore likely to control for initial health status, which is 
unobserved and might be correlated with drug vintage (although the sign of the potential 
correlation is not clear).   
The coefficients on the diagnosis category variables indicate differences in 
mortality rates associated with different diagnoses.  They are plotted in Figure 2.  By a 
large margin, people diagnosed with neoplasms had the highest mortality rate.  Diseases 
                                                 
8 Due to the large number of regressors (described below), I estimated a linear probability model, rather 
than a probit model. 
9 The mean of the dependent variable is 3.7%.  This is higher than the 3.1% figure reported above, which 
included ASES beneficiaries with no pharmacy claims.   9
of the blood and blood-forming organs and diseases of the skin and subcutaneous tissue 
are two other high-mortality conditions.  The lowest-mortality conditions include mental 
disorders, diseases of the nervous system and sense organs, and diseases of the 
musculoskeletal system and connective tissue.   
The coefficient on N_DISEASE is negative and highly significant, which is 
somewhat surprising.  This indicates that, conditional on the distribution of diagnoses a 
person had (and other covariates), the greater the effective number of diseases the person 
had, the lower the probability of death.   
The coefficients on the region dummy variables indicate differences in mortality 
rates associated with different regions.  They are plotted in Figure 3.  The mortality rate 
in Suroeste is almost 1.5 percentage points higher than the mortality rate in the second-
highest region, Este.  The regions with the lowest mortality rates are Montana, Guayama, 
and Arecibo. 
Estimates by condition.  In addition to estimating the model using data on the 
entire population of ASES beneficiaries with pharmaceutical claims, I also estimated the 
model separately for people with three specific diagnoses: (1) diseases of the circulatory 
system; (2) endocrine, nutritional and metabolic diseases, and immunity disorders 
(primarily diabetes); and (3) neoplasms.  All three of these conditions exhibit relatively 
high mortality rates (above 6%), and the first two are highly prevalent (affecting at least 
one-sixth of the population).  There were more than 2600 deaths in each group of people.   
Rather than reporting the complete set of estimates (as in Table 1) for each group, 
we report just the coefficients of the three drug-vintage variables, as well as means of key 
variables for each group, in Table 2. 
The first column of Table 2 shows estimates for the entire population (copied 
from Table 1).  The coefficients of the three drug-vintage variables (lines 11, 12, and 13) 
indicate differences between the mortality rates of people using drugs of different 
vintages.  By combining these coefficients with the average mortality rate (line 3) and the 
vintage distribution of drugs (lines 7-10), we can infer the (levels of) mortality rates of 
people using drugs of different vintages.
10   
                                                 
10 As argued above, if the mortality rate of people using pre-1970 drugs is equal to k, then the mortality rate 
of people using 1970s drugs is (k + β1970), the mortality rate of people using 1980s drugs is   10
The vintage-specific mortality rates are shown in lines 14-17 of Table 2 and 
plotted in Figure 4.  The estimated mortality rates are strictly declining with respect to 
drug vintage.  For pre-1970 drugs, the estimated mortality rate is 4.4%.  The mortality 
rates for 1970s, 1980s, and 1990s drugs are 3.6%, 3.0%, and 2.5%, respectively.  The 
differences in mortality rates are highly statistically significant (p-value < .0001).   
We can use these estimates to compare the actual mortality rate in the ASES 
population (resulting from the actual vintage distribution of drugs) to what the mortality 
rate would have been, given alternative hypothetical vintage distributions of drugs.  We 
consider two such alternative distributions: 
•  POST1970 = 0%: this would have characterized the distribution of drugs in 1970 
•  The vintage distribution of U.S. Medicaid Rx’s in 2000 
The results of these calculations are shown in Figure 5.  The actual mortality rate 
is about 16% (3.7% vs. 4.4%) lower than it would have been if all of the drugs utilized in 
2000 had been pre-1970 drugs.  There would have been almost 3800 more deaths in the 
ASES population during 2000-2002 if all of the drugs utilized in 2000 had been pre-1970 
drugs.  This suggests that new drugs introduced during 1970-2000 reduced the mortality 
rate by about 0.58% (= (1 / 30) * ln(4.4% / 3.7%)) per year.   
I would like to compare this figure to time-series mortality data for Puerto Rico 
during the period 1970-2000.  I don’t have time-series data on the age-adjusted mortality 
rate of Puerto Rico during this period, but I do have data on the age-adjusted mortality 
                                                                                                                                                 
(k + β1970 + β1980), etc.  To determine these mortality rates, we simply need to solve for k.  The overall 
mortality rate is the weighted average of these mortality rates, weighted by the percentage of people using 
drugs from each period:  
 
MORTAVG = (DRUG%PRE1970  * k) + (DRUG%1970s  * (k + β1970)) +  




MORTAVG = mean(DIED) 
DRUG%PRE1970 = mean(1 – POST70) 
DRUG%1970s  = mean(POST70 – POST80) 
DRUG%1980s  = mean(POST80 – POST90) 
DRUG%1990s  = mean(POST90) 
 
k = MORTAVG – ((DRUG%1970s  * β1970) + (DRUG%1980s  * (β1970 + β1980)) + (DRUG%1990s  * 
(β1970 + β1980 + β1990)))   11
                                                
rate of the U.S. during the period 1979-1998 (see Figure 6).
11  The age-adjusted mortality 
rate of the U.S. declined at an annual average rate of 0.71% during the period 1979-1998 
(and, due to the large jump between 1979 and 1980, it declined at an annual average rate 
of 0.92% during the period 1980-1998).  Moreover, in both Puerto Rico and the U.S., life 
expectancy increased much more rapidly in the 1970s than it has done since 1980.
12  
Therefore, our estimates’ implication that new drugs introduced during 1970-2000 
reduced the mortality rate by about 0.58% per year is not implausible.  At the same time, 
the estimates imply that the introduction of new drugs accounted for a significant fraction 
of the long-run decline in Puerto Rican mortality. 
As noted earlier, percentages of post-1980 and post-1990 Rx’s are much lower in 
ASES than they are in U.S. Medicaid.  The estimates imply that if the ASES vintage 
distribution were the same as U.S. Medicaid’s, ASES’s mortality rate would have been 
5.3% lower (3.5% vs. 3.7%), and there would have been almost 1100 fewer deaths in the 
ASES population during 2000-2002.   
Estimates by disease group.  Columns 2-4 of Table 2 present estimates of the 
model for each of three groups: (1) people with diseases of the circulatory system; (2) 
people with endocrine, nutritional and metabolic diseases, and immunity disorders 
(primarily diabetes); and (3) people with neoplasms.  Estimated vintage-specific 
mortality rates, by condition, are shown in Figure 7.  With only one exception (post-1990 
drugs for people with neoplasms), within each group the coefficients of all three drug-
vintage variables are negative and highly significant, which is consistent with the 
 
11 Source: CDC Wonder 1979-1998 Compressed Mortality data, 
12 Life expectancy at birth, both sexes: 
 
Period  Puerto 
Rico  U.S. 
1970-1975 72.2  71.5 
1975-1980 73.4  73.3 
1980-1985 73.8  74 
1985-1990 74.6  74.4 
1990-1995 73.9  74.9 
1995-2000 74.9  76.2 
Source: Population Division of the Department of Economic and Social Affairs of the United Nations 
Secretariat, World Population Prospects: The 2002 Revision and World Urbanization Prospects: The 2001 
Revision, http://esa.un.org/unpp, 25 May 2003; 5:45:45 PM.   12
hypothesis that ASES beneficiaries using newer drugs during January-June 2000 were 
less likely to die by the end of 2002, conditional on the covariates.   
 
IV.  Summary 
 
The Puerto Rico Health Insurance Administration (ASES) contracts with private 
managed care organizations to provide health care services for approximately 1.5 million 
people, or 40% of the population of Puerto Rico.  We examined the impact of the vintage 
(original FDA approval year) of drugs used to treat a patient on the probability of 
survival, conditional on demographic characteristics (age, sex, and region), utilization of 
medical services, and the nature and complexity of illness, using ASES data covering 
over half a million people.  I could not control for education and income, but to be 
eligible for Medicaid in Puerto Rico, annual income of a family of four could not exceed 
$16,440 (in the year 2002).   
We found that ASES beneficiaries using newer drugs during January-June 2000 
were less likely to die by the end of 2002, conditional on the covariates.   The estimated 
mortality rates are strictly declining with respect to drug vintage.  For pre-1970 drugs, the 
estimated mortality rate is 4.4%.  The mortality rates for 1970s, 1980s, and 1990s drugs 
are 3.6%, 3.0%, and 2.5%, respectively.  The differences in mortality rates are highly 
statistically significant (p-value < .0001).   
The actual mortality rate is about 16% (3.7% vs. 4.4%) lower than it would have 
been if all of the drugs utilized in 2000 had been pre-1970 drugs.  This suggests that new 
drugs introduced during 1970-2000 reduced the mortality rate by about 0.58% per year.  
This is not implausible, in light of the time-series data on mortality.  The introduction of 
new drugs appears to have accounted for a significant fraction of the long-run decline in 
Puerto Rican mortality. 
Percentages of post-1980 and post-1990 Rx’s are much lower in ASES than they 
are in U.S. Medicaid.  The estimates imply that if the ASES vintage distribution were the 
same as U.S. Medicaid’s, ASES’s mortality rate would have been 5.3% lower (3.5% vs. 
3.7%).  Use of older drugs in Puerto Rico’s Medicaid program may be partly attributable 
to the fact that, in Puerto Rico, the physician bears the costs of the drugs—the cost is 
deducted from the physician’s capitation payment.     13
In addition to estimating the model for the entire ASES population, we estimated 
the model separately for three groups: (1) people with diseases of the circulatory system; 
(2) people with endocrine, nutritional and metabolic diseases, and immunity disorders 
(primarily diabetes); and (3) people with neoplasms.  With only one exception, within 
each group the coefficients of all three drug-vintage variables were negative and highly 
significant. 
In this study, we did not control for the effect of the vintage of medical products 
and services other than drugs on survival, and this may have affected our estimates of the 
effect of drug vintage.  We plan to address this issue in future research.   14
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Vintage-specific mortality rates, by condition
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pre 1970 1970s 1980s 1990s
Difference is not
statistically significantVariable Estimate Standard error t Value Pr > |t|
Drug vintage variables
POST70 -0.0075 0.0009 -8.29 <.0001
POST80 -0.0056 0.0010 -5.48 <.0001
POST90 -0.0057 0.0014 -3.98 <.0001
Utilization variables
Number of medical claims 0.0031 0.0000 72.20 <.0001
Number of pharmacy claims 0.0011 0.0000 28.59 <.0001
Number of hospital claims 0.0053 0.0001 49.05 <.0001
Diagnosis category variables
infectious and parasitic diseases 0.0157 0.0017 9.28 <.0001
neoplasms 0.1558 0.0029 54.48 <.0001
endocrine, nutritional and metabolic diseases, and 
immunity disorders 0.0003 0.0014 0.19 0.8487
diseases of the blood and blood-forming organs
0.0350 0.0035 10.03 <.0001
mental disorders -0.0011 0.0014 -0.77 0.4386
diseases of the nervous system and sense organs
-0.0049 0.0015 -3.35 0.0008
diseases of the circulatory system 0.0048 0.0013 3.78 0.0002
diseases of the respiratory system 0.0096 0.0010 9.25 <.0001
diseases of the digestive system 0.0092 0.0017 5.55 <.0001
diseases of the genitourinary system 0.0091 0.0014 6.39 <.0001
diseases of the skin and subcutaneous tissue 0.0121 0.0019 6.34 <.0001
diseases of the musculoskeletal system and 
connective tissue -0.0229 0.0014 -16.28 <.0001
congenital anomalies 0.0012 0.0051 0.23 0.8191
certain conditions originating in the perinatal period
-0.0157 0.0109 -1.45 0.1479
symptoms, signs, and ill-defined conditions 0.0096 0.0014 6.73 <.0001
N_DISEASE -0.0014 0.0002 -8.42 <.0001
Region dummy variables
Aguadilla 0.6358 0.0382 16.63 <.0001
Arecibo 0.6304 0.0382 16.49 <.0001
Bayamon 0.6357 0.0382 16.62 <.0001
Este 0.6428 0.0382 16.81 <.0001
Fajardo 0.6421 0.0382 16.79 <.0001
Guayama 0.6298 0.0382 16.47 <.0001
Mayaguez 0.6390 0.0382 16.71 <.0001
Montana 0.6285 0.0382 16.43 <.0001
Suroeste 0.6573 0.0383 17.18 <.0001
Table 1
Estimates of mortality model, full sample
N = 539,750.  The dependent variable is a dummy variable equal to one if the person died during 2000-2002, 


















N (Number of beneficiaries with 
pharmacy claims) 539,750 114,656 91,087 15,758
2 Number of deaths 19,820 9,486 5,513 2,634
means
3 died 3.7% 8.3% 6.1% 16.7%
4 post1970 63.2% 69.2% 67.5% 65.9%
5 post1980 29.7% 39.7% 37.5% 34.4%
6 post1990 8.2% 10.9% 9.9% 9.5%
vintage distribution
7 pre 1970 36.8% 30.8% 32.5% 34.1%
8 1970s 33.5% 29.5% 30.1% 31.5%
9 1980s 21.5% 28.8% 27.6% 24.9%
10 1990s 8.2% 10.9% 9.9% 9.5%
vintage coefficients
11 POST1970 -0.0075 -0.0311 -0.0154 -0.0339
std. error 0.0009 0.0037 0.0035 0.0113
t-statistic -8.29 -8.42 -4.36 -2.99
p-value   <.0001  <.0001  <.0001 0.0028
12 POST1980 -0.0056 -0.0075 -0.0095 -0.0359
std. error 0.0010 0.0037 0.0035 0.0122
t-statistic -5.48 -2.05 -2.68 -2.94
p-value   <.0001 0.0405 0.0074 0.0032
13 POST1990 -0.0057 -0.0143 -0.0109 0.0092
std. error 0.0014 0.0046 0.0047 0.0172
t-statistic -3.98 -3.14 -2.32 0.53
p-value   <.0001 0.0017 0.0204 0.5929
Implied mortality rates
14 pre 1970 4.4% 10.9% 7.6% 20.1%
15 1970s 3.6% 7.8% 6.0% 16.7%
16 1980s 3.0% 7.0% 5.1% 13.1%
17 1990s 2.5% 5.6% 4.0% 14.0%
Table 2
Drug-vintage coefficients and related estimates, by disease group